1995Therapeutic Drug MonitoringRequires access

Therapeutic Drug Monitoring of Cyclosporin G

Randall W. Yatscoff, Loralie J. Langman, Donald F. LeGatt

Open publisher page 0 citations

Abstract

Therapeutic drug monitoring has been an integral part of the clinical investigations of cyclosporin G (OG37-325 CsG), an analogue of cyclosporin A (CsA). In general, analytic approaches used for monitoring of CsA have been used for the measurement of CsG. However, the validity of this approach may be questioned, as there are significant differences between the two drugs in the areas of blood distribution, pharmacokinetics, steady-state concentration of metabolites, and biases with the various immunoassays adapted for measurement of the drug. Based on the above, it is not appropriate to assume that the therapeutic drug monitoring protocols previously established for CsA are applicable to CsG. The latter drug should be treated as a new compound, with the development of independent therapeutic monitoring guidelines. Similar approaches should be used for other immunosuppressive drugs.

About this research paper

What this paper is about

Therapeutic drug monitoring has been an integral part of the clinical investigations of cyclosporin G (OG37-325 CsG), an analogue of cyclosporin A (CsA). In general, analytic approaches used for monitoring of CsA have been used for the measurement of CsG. However, the validity of this approach may be questioned, as there are significant differences between the two drugs in the areas of blood distribution, pharmacokinetics, steady-state concentration of metabolites, and biases with the various immunoassays adapted for measurement of the drug. Based on the above, it is not appropriate to assume that the therapeutic drug monitoring protocols previously established for CsA are applicable to CsG. The latter drug should be treated as a new compound, with the development of independent therapeutic monitoring guidelines. Similar approaches should be used for other immunosuppressive drugs.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Therapeutic drug monitoring has been an integral part of the clinical investigations of cyclosporin G (OG37-325 CsG), an analogue of cyclosporin A (CsA). In general, analytic approaches used for monitoring of CsA have been used for the measurement of CsG. However, the validity of this approach may be questioned, as there are significant differences between the two drugs in the areas of blood distribution, pharmacokinetics, steady-state concentration of metabolites, and biases with the various immunoassays adapted for measurement of the drug. Based on the above, it is not appropriate to assume that the therapeutic drug monitoring protocols previously established for CsA are applicable to CsG. The latter drug should be treated as a new compound, with the development of independent therapeutic monitoring guidelines. Similar approaches should be used for other immunosuppressive drugs.

Key concepts: Therapeutic drug monitoring, Pharmacokinetics, Drug, Pharmacology, Medicine, Therapeutic index, Drug-drug interaction, Distribution (mathematics)

Related papers

Back to paper searchBrowse research topicsOriginal source
Therapeutic Drug Monitoring of Cyclosporin G — Research Paper | ScholarLens